Skip to contentA
Aclaris Therapeutics, Inc.
A
ACRSAclaris Therapeutics, Inc. Q3 2021 · 10-Q
Revenue$1.66M$1.66M+14.5% vs Q3 2020 Net Income-$21.15M-$21.15MN/M vs Q3 2020 EPS Diluted-$0.35-$0.35N/M vs Q3 2020 Operating Income-$20,295,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Aclaris Therapeutics, Inc. · CIK 1557746 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$10,662,000N/M Margins · derivedOperating margin-1223.3%−501.1 pt vs Q3 2020
Net margin-1274.6%−539.0 pt vs Q3 2020
ended Sep 30, 2021 · filed Nov 2, 2021 · 33 d after period end